Dr. Felton has disclosed six inventions focused on drug delivery and has one pending patent application related to a transdermal delivery system.
Dr. Felton is an inventor of a technology that uses stable isotope-labeled excipients (inactive ingredients) in dosage forms for identifying and detecting counterfeit drug products. Another technology uses stable isotope-labeled excipients as a method to determine if a patient has taken the drug. After ingestion, the labeled compound is released and can be measured in breath, urine, feces, saliva, or blood. She also has developed stable, orally administered pharmaceutical preparations of exogenous precursor molecules used in the formation of collagen and prostaglandins for the treatment of pain and joint deterioration associated with arthritis and other degenerative conditions. Additionally, Dr. Felton is a co-inventor of a transdermal delivery method to administer tyrosine kinase inhibitors loaded in protocells, surface-modified supported lipid bilayer particles. This technology provides a novel approach for the delivery of certain chemotherapeutic agents.
Dr. Felton’s primary research interests are focused on polymeric film-coating technology and modified- release, drug-delivery systems. Ongoing studies are investigating the film-substrate interface, novel methodologies to characterize the physical, mechanical, adhesive, and drug-release properties of coated solids, and the influence of formulation and process variables on product performance. Another research area of interest involves the penetration of chemicals through skin and simulated tissue models. In addition, Dr. Felton is also involved in the formulation development and cGMP manufacturing of solid-dosage forms for use in clinical trials.
Pending Patent Application
Porous Nanoparticle-Supported Lipid Bilayers (Protocells) for Targeted Delivery Including Transdermal Delivery of Cargo and Methods Thereof